English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background   Extended-spectrum  β -lactamase (ESBL)- and AmpC- β -lactamase (ESBL)- and AmpC- Enterobacteriaceae  have recently emerged as a public threat in the treatment of nosocomial as well as community-acquired infections. Very little information is currently available about its existence in Nepal. We, therefore, aim to determine the prevalence of ESBL and AmpC- β -lactamase (ESBL)- and AmpC- Enterobacteriaceae  have recently emerged as a public threat in the treatment of nosocomial as well as community-acquired infections. Very little information is currently available about its existence in Nepal. We, therefore, aim to determine the prevalence of ESBL and AmpC-    Methods   During a 6-month period (November 2014–April 2015), a total of 190 stool specimens from 190 participants were obtained from different population. Of the total 260 fecal isolates, 152 from outpatient department (OPD) and 108 from healthy volunteer were collected. Stool specimens were cultured and enterobacterial isolates were subjected to antimicrobial susceptibility tests according to the standard microbiologic guidelines. ESBL was screened using ceftazidime (CAZ, 30  μ g) and cefotaxime (CTX, 30  μ g) and cefotaxime (CTX, 30  β -lactamase (ESBL)- and AmpC-    Results   The prevalence of ESBL, AmpC- β -lactamase (ESBL)- and AmpC- β -lactamase (ESBL)- and AmpC- Enterobacteriaceae  have recently emerged as a public threat in the treatment of nosocomial as well as community-acquired infections. Very little information is currently available about its existence in Nepal. We, therefore, aim to determine the prevalence of ESBL and AmpC- E. coli  was 70.2% followed by  K. pneumoniae  (12.7%), and among AmpC- β -lactamase (ESBL)- and AmpC- E. coli  was 70.2% followed by  E. coli  was 70.2% followed by  K. pneumoniae  (12.7%), and among AmpC- K. pneumoniae  (12.7%), and among AmpC- C. freundii  2/7 (28.57%) were detected highest among AmpC- β -lactamase (ESBL)- and AmpC-    Conclusion   Our study revealed a high prevalence of ESBL- and AmpC- β -lactamase-producing enteric pathogen in Nepalese OPD and healthy population. The significant increase of these isolates and increased rate of drug resistance indicates a serious threat that stress the need to implement the surveillance system and a proper control measure so as to limit the spread of ESBL-producing  Enterobacteriaceae  (ESBL-PE) in both OPD as well as in community. Therefore, healthcare providers need to be aware that ESBL- and AmpC- β -lactamase-producing strains are not only circulating in hospital environments but also in the community and should be dealt with accordingly. β -lactamase (ESBL)- and AmpC- Enterobacteriaceae  have recently emerged as a public threat in the treatment of nosocomial as well as community-acquired infections. Very little information is currently available about its existence in Nepal. We, therefore, aim to determine the prevalence of ESBL and AmpC- β -lactamase (ESBL)- and AmpC-

the canadian journal of infectious diseases and medical microbiology/canadian journal of infectious diseases and medical microbiology

Carriage of Extended-Spectrum-β-Lactamase- and AmpC-β-Lactamase-Producing Enterobacteriaceae (ESBL-PE) in Healthy Community and Outpatient Department (OPD) Patients in Nepal